Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01747811
Other study ID # 2010-P-001570/1
Secondary ID
Status Completed
Phase N/A
First received December 6, 2012
Last updated November 2, 2016
Start date December 2010
Est. completion date December 2013

Study information

Verified date November 2016
Source University of Arizona
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

Mild traumatic brain injuries (mTBI) or "concussions" are an increasingly prevalent injury in our society. Patients with post-concussion syndrome have been shown to have deficits on tests of short term memory, divided attention, multi-tasking, information processing speed, and reaction time, as well as alteration in mood and emotional functioning. Many patients have other vague complaints including fatigue, dizziness, irritability, sleep disturbances, and chronic headaches. Furthermore, sleep disruption of one of the most common complaints in patients suffering from traumatic brain injuries, with as many as 40 to 65% of patients with mTBI complaining of insomnia. Sleep problems in these patients are associated with poorer outcome, while resolution of the sleep disturbance is associated with improvement in cognitive functioning.

Despite recent evidence of the correlation between sleep quality and recovery from traumatic brain injury, and the well-established role of sleep in neural plasticity and neurogenesis, there have been virtually no direct studies of the causal effects of sleep on recovery following mTBI. However, it is quite likely that sleep plays a critical role in recovery following brain injury.

A particularly promising non-pharmacologic approach that shows potential in improving/modifying abnormalities of the circadian rhythm and sleep-wake schedule is bright light therapy. For the proposed investigation, we hypothesize that bright light therapy may be helpful in improving the sleep of patients with a recent history of mTBI and may also have other mood elevating effects, both of which should promote positive treatment outcome in these individuals. Bright light therapy may increase the likelihood that they will recover more quickly, benefit more extensively from other forms of therapy, and build emotional and cognitive resilience.


Recruitment information / eligibility

Status Completed
Enrollment 32
Est. completion date December 2013
Est. primary completion date December 2013
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria:

- Age range between 18 and 50.

- Subjects must be right handed.

- The primary language of the subjects must be English.

- Subjects have experienced a "concussion" or mTBI within the preceding 18 months, but no sooner that 4 weeks prior to their screening. The occurrence of a concussion or mTBI must be documented by a medical report or other professional witness documentation.

- If documented, Glasgow Coma Scale in the range of 13-15 following the injury.

- Subjects must have complaints of sleep difficulties that emerged or worsened following the most recent head injury.

- At least half of subjects must have evidence of sleep onset insomnia or delayed sleep phase disorder.

Exclusion Criteria:

- Any other history of neurological illness, current Diagnostic and Statistical Manual (DSM-IV) Axis I disorder, lifetime history of psychotic disorder, or head injury with loss of consciousness > 30 minutes

- Complicating medical conditions that may influence the outcome of neuropsychological assessment or functional imaging (e.g., HIV, brain tumor, etc.)

- Mixed or left-handedness

- Abnormal visual acuity that is not corrected by contact lenses

- Contraindicated conditions noted by the manufacture of the light device such as the use of photosynthesizing medications, history of cataract surgery, and pre-existing eye conditions.

- Metal within the body, claustrophobia, or other contraindications for neuroimaging

- Less than 9th grade education

- Excess current alcohol use (more than 2 instances of intake of 5+ drinks (men) when or 4+ drinks (women) when drinking in the past two months, and/or on average drinking > 2 drinks per day (men); > 1 drinks per day (women) during the past two months

- History of alcoholism or substance use disorder

- Significant use of illicit drugs

- History of marijuana use within the past 6 weeks, use of marijuana before the age of 16, and/or use of > 20 marijuana cigarettes throughout the participant's lifetime.

- Subjects who engage in shift-work, night work, or who have substantially desynchronized work-sleep schedules (i.e., sleeping later than 10:00 a.m. more than once a week) will be excluded

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment


Intervention

Device:
wavelength-1 bright light
6 weeks of daily light exposure, 30 minutes per morning
wavelength-2 bright light
6 weeks of daily light exposure, 30 minutes per morning

Locations

Country Name City State
United States University of Arizona Medical Center Tucson Arizona

Sponsors (2)

Lead Sponsor Collaborator
University of Arizona U.S. Army Medical Research Acquisition Activity

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Change From Baseline in Beck Depression Inventory (BDI-II) Scores at 6 Weeks The Beck Depression Inventory (BDI-II) is a self report scale utilized for measuring the severity of depression. Scores can range from 0-63 (0 meaning minimal depressive symptoms, and 63 being severe depressive symptoms). Participants are given this on baseline and post treatment. Change from baseline at 6 weeks (post-treatment) No
Primary Performance on Multiple Sleep Latency Test (MSLT) The MSLT is a objective measure of sleepiness. Participants will take a brief nap 3 times during the 1st and second visit. The period of time between wake and sleep onset will be utilized as an objective measure of sleepiness (in minutes). A mean value will be calculated for the entirety of the pre-treatment napping periods and for the post treatment visits. Change from baseline performance at 6 weeks (post-treatment) No
Secondary Neural Activation During Functional Magnetic Resonance Imaging (fMRI) Executive Function Task Change from baseline in left prefrontal cortical response during a multi source interference task at six weeks. Methods utilized to assess activity in the left prefrontal cortex/inferior frontal operculum included a regions of interest analysis. Change from baseline performance at 6 weeks (post-treatment) No
Secondary Score on Pittsburgh Sleep Quality Index (PSQI) The Pittsburgh Sleep Quality Index is a self report measure of sleep quality. The overall score takes into account many different facets of sleep, such as sleep quality, sleep latency, sleep duration, sleep disturbances, etc. The scores range from 0-21, and any score that is equal to or greater than 5 is indicative of poor sleep quality. Change from baseline at 6 weeks (post-treatment) No
Secondary Actigraphy-measured Sleep Quality Actigraphy is an objective measure that determines sleep vs. wake. It is a watch with an accelerometer worn on the wrist. Sleep quality is determined by the amount of time in bed divided by the amount of time sleeping (in minutes). Change from baseline at 6 weeks (post-treatment) No
Secondary Performance on Neuropsychological Assessment The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) is a neuropsychological assessment that measures different facets of memory including the following: immediate memory, visuospatial/constructional, language, attention, and delayed memory. This is given to all participants on both pre and post treatment visits. The total range for this scale is 40-160. Lower values represent a worse outcome, and higher values represent an improved outcome. Change from baseline at 6 weeks (post-treatment) No
See also
  Status Clinical Trial Phase
Recruiting NCT05849064 - Concussion Treatment in Older Adults N/A
Terminated NCT04586179 - A Comparison Between Cardiovascular Exercise Modes Following Sport Related Concussion N/A
Not yet recruiting NCT05943561 - Biomarkers in Concussion
Completed NCT02721537 - Use of 31P MRS to Assess Brain NAD+ in Healthy Current and Former Collegiate Athletes N/A
Completed NCT03236389 - Brain Dynamics in Response to Jugular Vein Compression N/A
Completed NCT01832714 - Assessment of Oculomotor, Vestibular and Reaction Time Response Following a Concussive Event
Completed NCT04560400 - Reverse King-Devick Test and History of Multiple Concussions N/A
Completed NCT03678077 - Trends in Cohabitation Status, Academic Achievement and Socio-economic Indicators After Mild Traumatic Brain Injury
Recruiting NCT05262361 - Persistent Post-Concussion Symptoms With Convergence Insufficiency N/A
Recruiting NCT05105802 - Mindfulness-Based Intervention for Mild Traumatic Brain Injury N/A
Terminated NCT03123822 - Spectacles Lens in Concussed Kids N/A
Completed NCT04641832 - The Combined Effect of Chronic Cannabis Use and Subconcussive Head Impacts on Brain Health N/A
Completed NCT04074486 - Evaluation and Validation of a Multimodal Brain Function Biomarker With NPC
Withdrawn NCT04578743 - Exercise as Concussion Therapy Trial- 2 Phase 2
Completed NCT03671083 - Validation of Brain Function Assessment Algorithm for mTBI/Concussion
Completed NCT03170856 - The Effects of a Sub-maximal Exercise Program on Adolescents Who Sustained a Concussion N/A
Completed NCT05069948 - Delivery of Digital Cognitive Behavioural Therapy Following Concussion N/A
Recruiting NCT03889483 - Neurophysiological Measurements Using the NeuroCatchâ„¢ Platform in Pediatric Concussion N/A
Withdrawn NCT02959294 - Use of Adipose-Derived Stem/Stromal Cells in Concussion and Traumatic Brain Injuries Early Phase 1
Recruiting NCT06093295 - Non-invasive Brain Stimulation and Injury Risk Biomechanics N/A